Why Is FAETH THERAPEUTICS I (FTH) Stock Moving Today?

FTH stock closed down 9.52% at $35.37 on Friday, marking one of the largest single-day declines in recent weeks. The sharp drop came despite multiple buy ratings from new and existing coverage initiations in the past 36 hours. The stock opened with a small gap down and traded in a wide intraday range before closing near the session low.

What Happened

Faeth Therapeutics faced a significant sell-off despite a flurry of positive analyst activity. Three separate coverage initiations from Guggenheim, Lucid Capital, and TD Cowen all assigned Buy ratings to the stock. Lucid Capital and Needham also set price targets of $56 and $60 respectively. However, the market reacted negatively, with the stock falling from a morning high of $39.89 to a low of $34.88 by the close. The session volume of 0.1 million shares was above the 3-month average by 70%, suggesting increased participation from traders. The stock has now declined 7.6% over the past 8 sessions, falling from $39.00 to $36.03.

What The Data Shows

The stock opened at $38.75, reflecting a -0.9% gap down from the previous close of $39.09. It traded in a volatile range before closing at $35.37, near the session low. The 52-week range is $7.45 to $42.14, and the stock closed near the lower end of that range. Insiders have been active buyers in the last 90 days, with four transactions totaling $1.2 million, including recent purchases by the CFO and CEO. The stock also printed two fresh 52-week highs and 29 fresh 52-week lows on September 15, 2026.

What To Watch

The stock has no scheduled earnings date in the immediate future. Traders should monitor the breadth of analyst coverage and how the market reacts to continued buy ratings and price targets. The stock remains unprofitable with an EPS TTM of -82.46 and a market cap of $967.5 million.

Why is FTH stock moving today?

FAETH THERAPEUTICS I (FTH) is drawing unusual attention today. Our newswire has captured 4 stories on FTH across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "Cantor Fitzgerald reiterates Faeth Therapeutics stock rating" (Investing.com Analyst Ratings).

Is FTH a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of FTH coverage reads 52/100 over 4 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.